Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Study on the Effect of Infusion Timing of Immune Checkpoint Inhibitors on Pathologic Response in Patients With Resectable Stage II-III Non-Small Cell Lung Cancer Undergoing Neoadjuvant Therapy

NCT07251582 is registered in ClinicalTrials.gov with Hunan Province Tumor Hospital as lead sponsor.

NCT NCT07251582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07251582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Study on the Effect of Infusion Timing of Immune Checkpoint Inhibitors on Pathologic Response in Patients With Resectable Stage II-III Non-Small Cell Lung Cancer Undergoing Neoadjuvant Therapy
Lead sponsor
Hunan Province Tumor Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
August 12, 2026
Completion date
May 31, 2029
Enrollment
186 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

resectable stage ii-iii non-small cell lung cancer (nsclc)